HIV model parameter estimates from interruption trial data including drug efficacy and reservoir dynamics

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Luo, Rutao ^a   Piovoso, Michael J ^b   Martinez Picado, Javier ^c,d   Zurakowski, Ryan ^a  

^a UNIVERSITY OF DELAWARE   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c Institut de Recerca de la Sindrome de Inmunodeficencia Adquirida   (Spain)

^d INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DRUG EFFICACY; DYNAMICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; MATHEMATICAL PARAMETERS; MEASUREMENT; MONTE CARLO METHOD; NONHUMAN; NONLINEAR SYSTEM; PROBABILITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RESERVOIR; TIME SERIES ANALYSIS; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BAYES THEOREM; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS; LEAST-SQUARES ANALYSIS; MODELS, STATISTICAL; NONLINEAR DYNAMICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; VIRAL LOAD; WITHHOLDING TREATMENT;

EID: 84864015446     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040198     Document Type: Article

References (47)

1. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, et al. (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373: 117-122.
2. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, et al. (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123-126.
3. Nelson GW, Perelson AS, (1995) Modeling defective interfering virus therapy for AIDS: conditions for HIV survival. Math Biosci 125: 127-153.
4. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD, (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271: 1582-1586.
5. Bortz DM, Nelson PW, (2006) Model selection and mixed-effects modeling of HIV infection dynamics. Bull Math Biol 68: 2005-2025.
6. Ruiz L, Carcelain G, Martnez-Picado J, Frost S, Marfil S, et al. (2001) HIV dynamics and t-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS 15: F19-F27.
7. Stafford MA, Corey L, Cao Y, Daar ES, Ho DD, et al. (2000) Modeling plasma virus concentration during primary HIV infection. J Theor Biol 203: 285-301.
8. Xia X, Moog CH, (2003) Identifiability of nonlinear systems with application to HIV/AIDS models. IEEE T Automat Contr 48: 330-336.
9. Wu H, Zhu H, Miao H, Perelson AS, (2008) Parameter identifiability and estimation of HIV/AIDS dynamic models. Bull Math Biol 70: 785-799.
10. Miao H, Dykes C, Demeter LM, Wu H, (2009) Differential equation modeling of HIV viral fitness experiments: model identification, model selection, and multimodel inference. Biometrics 65: 292-300.
11. Liang H, Miao H, Wu H, (2010) Estimation of constant and time-varying dynamic parameters of HIV infection in a nonlinear differential equation model. Ann Appl Stat 4: 460-483.
12. Wu H, Huang Y, Acosta EP, Rosenkranz SL, Kuritzkes DR, et al. (2005) Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance. J Acquir Immune Defic Syndr 39: 272-283.
13. Huang Y, Liu D, Wu H, (2006) Hierarchical bayesian methods for estimation of parameters in a longitudinal HIV dynamic system. Biometrics 62: 413-423.
14. Huang Y, (2008) Long-term HIV dynamic models incorporating drug adherence and resistance to treatment for prediction of virological responses. Computational Statistics & Data Analysis 52: 3765-3778.
15. Huang Y, Wu H, Acosta EP, (2010) Hierarchical bayesian inference for HIV dynamic differential equation models incorporating multiple treatment factors. Biom J 52: 470-486.
16. Putter H, Heisterkamp SH, Lange JMA, de Wolf F, (2002) A Bayesian approach to parameter estimation in HIV dynamical models. Stat Med 21: 2199-2214.
17. Markowitz M, Louie M, Hurley A, Sun E, Di Mascio M, et al. (2003) A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol 77: 5037-5038.
18. Perelson A, (1993) Dynamics of HIV infection of CD4+ T cells. Mathematical Biosciences 114: 81-125.
19. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, et al. (1997) Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387: 188-191.
20. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, et al. (1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337: 734-739.
21. Dornadula G, Zhang H, VanUitert B, Stern J, Livornese L, et al. (1999) Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 282: 1627-1632.
22. Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, et al. (2003) New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 41: 4531-4536.
23. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278: 1295-1300.
24. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, et al. (1997) Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 94: 13193-13197.
25. Luo R, Piovoso M, Zurakowski R, (2009) A generalized multi-strain model of HIV evolution with implications for drug-resistance management. In: Proc. American Control Conference. pp. 2295-2300 doi:10.1109/ACC.2009.5160358.
26. Rong L, Perelson AS, (2009) Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput Biol 5: e1000533.
27. Rong L, Perelson AS, (2009) Modeling HIV persistence, the latent reservoir, and viral blips. Journal of Theoretical Biology 260: 308-331.
28. Smith DM, Wong JK, Shao H, Hightower GK, Mai SHT, et al. (2007) Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission. J Infect Dis 196: 356-360.
29. Gunthard HF, Havlir DV, Fiscus S, Zhang ZQ, Eron J, et al. (2001) Residual human immunodeficiency virus (HIV) type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal uid after suppression of viremia for 2 years. J Infect Dis 183: 1318-1327.
30. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, et al. (2008) Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 105: 3879-3884.
31. Blankson JN, Persaud D, Siliciano RF, (2002) The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 53: 557-593.
32. Schrager LK, D'Souza MP, (1998) Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 280: 67-71.
33. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, et al. (1997) Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387: 183-188.
34. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, et al. (1995) In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1: 1284-1290.
35. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, et al. (2003) Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9: 727-728.
36. Ljung L, Glad S, (1994) On global identifiability for arbitrary model parameterizations. Automatica 30: 265-76.
37. Saccomani MP, Audoly S, D'Angio L, (2003) Parameter identifiability of nonlinear systems: the role of initial conditions. Automatica 39: 619-632.
38. Saccomani MP, Audoly S, Bellu G, D'Angio L, (2010) Examples of testing global identifiability of biological and biomedical models with the daisy software. Computers in Biology and Medicine 40: 402-407.
39. Ritt JF, (1950) Differential algebra. Providence, R.I.: American Mathematical Society.
40. Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, et al. (1999) Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. The Lancet 354: 1782-1785.
41. Luo R, Zurakowski R, (2008) A new strategy to decrease risk of resistance emerging during therapy switching in HIV treatment. In: Proc. American Control Conference. pp. 2112-2117 doi:10.1109/ACC.2008.4586804.
42. Luo R, Cannon L, Hernandez J, Piovoso M, Zurakowski R, (2011) Controlling the evolution of resistance. J Process Control 21: 367-378.
43. Luo R, Piovoso MJ, Martinez-Picado J, Zurakowski R, (2011) Optimal Antiviral Switching to Minimize Resistance Risk in HIV Therapy. PLoS ONE 6: e27047.
44. Martinez-Cajas JL, Wainberg MA, (2008) Antiretroviral therapy: optimal sequencing of therapy to avoid resistance. Drugs 68: 43-72.
45. Cardozo EF, Zurakowski R, (2012) Robust Closed-Loop Minimal Sampling Method for HIV Therapy Switching Strategies. Biomedical Engineering, IEEE Transactions on 59: In press doi:10.1109/TBME.2012.2201479.
46. Ferreira J, Hernandez-Vargas EA, Middleton RH, (2011) Computer simulation of structured treatment interruption for HIV infection. Comput Methods Programs Biomed 104: 50-61.
47. Hernandez-Vargas E, Colaneri P, Middleton R, Blanchini F, (2011) Discrete-time control for switched positive systems with application to mitigating viral escape. International Journal of Robust and Nonlinear Control 21: 1093-111.